Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0293263 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Phoomintara Longsompurana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand. Hauptthemen laut MEDLINE: COVID-19, Single-Domain Antibodies. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand.
Abstract (Originalsprache)
The COVID-19 pandemic has created an urgent need for effective therapeutic and diagnostic strategies to manage the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the emergence of numerous variants of concern (VOCs) has made it challenging to develop targeted therapies that are broadly specific in neutralizing the virus. In this study, we aimed to develop neutralizing nanobodies (Nbs) using computational techniques that can effectively neutralize the receptor-binding domain (RBD) of SARS-CoV-2 VOCs. We evaluated the performance of different protein-protein docking programs and identified HDOCK as the most suitable program for Nb/RBD docking with high accuracy. Using this approach, we designed 14 novel Nbs with high binding affinity to the VOC RBDs. The Nbs were engineered with mutated amino acids that interacted with key amino acids of the RBDs, resulting in higher binding affinity than human angiotensin-converting enzyme 2 (ACE2) and other viral RBDs or haemagglutinins (HAs). The successful development of these Nbs demonstrates the potential of molecular modeling as a low-cost and time-efficient method for engineering effective Nbs against SARS-CoV-2. The engineered Nbs have the potential to be employed in RBD-neutralizing assays, facilitating the identification of novel treatment, prevention, and diagnostic strategies against SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
- Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
- Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence for Molecular Biology and Genomics of Shrimp, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence for Molecular Crop, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
- Institute of Theoretical Chemistry, University of Vienna, Vienna, Austria.
ORCID-Profile: Rungtiva P Poo-Arporn
Förderung
- National Research Council of Thailand
Zitieren
APA
Longsompurana, P., Rungrotmongkol, T., Plongthongkum, N., Wangkanont, K., Wolschann, P., & Poo-Arporn, R. P. (2023). Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2. PLOS ONE. https://doi.org/10.1371/journal.pone.0293263
Vancouver
Longsompurana P, Rungrotmongkol T, Plongthongkum N, Wangkanont K, Wolschann P, Poo-Arporn RP. Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2. PLOS ONE. 2023. doi:10.1371/journal.pone.0293263
BibTeX
@article{Longsompurana2023,
author = {Longsompurana, Phoomintara and Rungrotmongkol, Thanyada and Plongthongkum, Nongluk and Wangkanont, Kittikhun and Wolschann, Peter and Poo-Arporn, Rungtiva P},
title = {Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0293263}
}
EUVIMED